caa a22 4500 475785304 CHVBK 20180406123656.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1007/s004310050045 doi (NATIONALLICENCE)springer-10.1007/s004310050045 Variable use of therapeutic interventions for children with human immunodeficiency virus type 1 infection in Europe [Elektronische Daten] [S. Bernardi, C. Thorne, M. -L. Newell, C. Giaquinto, P. -A. Tovo, P. Rossi] Although a range of antiretroviral drugs are available for use in children, the appropriate paediatric regimen remains unclear. In a survey to investigate policies and practices relating to the therapeutic management of children infected by the human immunodeficiency virus (HIV), a postal questionnaire was sent to a named paediatrician in 70 major HIV centres in 13 European countries in early 1998. A total of 64 paediatricians (91%) responded. Pneumocystis carinii pneumonia prophylaxis was found to be routine in all centres, although considerable variation existed regarding the time of starting and stopping therapy. Prophylaxis for fungal infections and recurrent bacterial infections was common, with cytomegalovirus prophylaxis being less frequent. Although most centres (89%) used all five currently available nucleoside analogues (ziduvodine, lamivudine, stavudine, didanosine, zalcitabine), there was considerable variability regarding the availability of protease inhibitors. Most respondents delayed initiation of antiretroviral therapy until evidence of disease progression was apparent. The initial prescription of 38% of clinicians was triple therapy and that of 57% prescribed double therapy. Policies varied regarding the modification to regimens in response to disease progression and emergence of side effects and drug resistance. Clinical practice was informed by a number of sources, including centre-specific and national guidelines. Most respondents affirmed the need for European guidelines. Conclusion Approaches to the therapeutic management of paediatric human immunodeficiency virus infection differ across Europe. Springer-Verlag Berlin Heidelberg, 2000 Key words Human immunodeficiency virus nationallicence Antiretroviral drug therapy nationallicence Prophylactic drug therapy nationallicence Management nationallicence Bernardi S. Bambino Gesù Children's Hospital, Rome, Italy, IT aut Thorne C. Department of Epidemiology and Public Health, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK e-mail: M.Newell@ich.ucl.ac.uk Tel.: +44-171-829-8699; Fax: +44-171-242-2723, GB aut Newell M. -L Department of Epidemiology and Public Health, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK e-mail: M.Newell@ich.ucl.ac.uk Tel.: +44-171-829-8699; Fax: +44-171-242-2723, GB aut Giaquinto C. Department of Paediatrics, University of Padua, Padua, Italy, IT aut Tovo P. -A Department of Paediatrics, University of Turin, Turin, Italy, IT aut Rossi P. Bambino Gesù Children's Hospital, Rome, Italy, IT aut https://doi.org/10.1007/s004310050045 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s004310050045 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bernardi S. Bambino Gesù Children's Hospital, Rome, Italy, IT aut NATIONALLICENCE 700 1- Thorne C. Department of Epidemiology and Public Health, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK e-mail: M.Newell@ich.ucl.ac.uk Tel.: +44-171-829-8699; Fax: +44-171-242-2723, GB aut NATIONALLICENCE 700 1- Newell M. -L Department of Epidemiology and Public Health, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK e-mail: M.Newell@ich.ucl.ac.uk Tel.: +44-171-829-8699; Fax: +44-171-242-2723, GB aut NATIONALLICENCE 700 1- Giaquinto C. Department of Paediatrics, University of Padua, Padua, Italy, IT aut NATIONALLICENCE 700 1- Tovo P. -A Department of Paediatrics, University of Turin, Turin, Italy, IT aut NATIONALLICENCE 700 1- Rossi P. Bambino Gesù Children's Hospital, Rome, Italy, IT aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer